Fairmount Funds Management’s Insmed INSM Stock Holding History

Fairmount Funds Management’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,336,368	Closed	-$28.8M	–	22
2022 Q3	$28.8M	Buy	1,336,368 +10,000	+0.8%	+$240K	5.06%	7
2022 Q2	$26.2M	Sell	1,326,368 -622,416	-32%	-$13M	5.99%	7
2022 Q1	$45.8M	Buy	1,948,784 +635,177	+48%	+$14.8M	10.83%	1
2021 Q4	$35.8M	Hold	1,313,607	–	–	11.8%	2
2021 Q3	$36.2M	Buy	1,313,607 +29,720	+2%	+$780K	13.16%	1
2021 Q2	$36.5M	Buy	1,283,887 +322,090	+33%	+$9.56M	15.02%	1
2021 Q1	$32.8M	Hold	961,797	–	–	13.81%	1
2020 Q4	$32M	Sell	961,797 -95,000	-9%	-$3.47M	11.45%	1
2020 Q3	$34M	Buy	1,056,797 +46,000	+5%	+$1.32M	14.39%	1
2020 Q2	$27.8M	Sell	1,010,797 -10,000	-1%	-$237K	12.42%	2
2020 Q1	$16.4M	Buy	1,020,797 +31,798	+3%	+$754K	9.92%	3
2019 Q4	$23.6M	Buy	+988,999	New	+$20.1M	14.31%	2

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fairmount Funds Management's INSM Position: Q4 2022 in Review

Fairmount Funds Management sold out of Insmed (INSM) in Q4 2022, closing a stake of 1,336,368 shares — an estimated $28.8M sold.

Fairmount Funds Management first reported a position in INSM in Q4 2019 and held it in 12 quarters. The position peaked at $45.8M in Q1 2022. 225 funds tracked by Wall St. Rank hold INSM as of Q4 2022.

Fairmount Funds Management reported no remaining Insmed position as of Q4 2022 after selling out during the quarter.
Fairmount Funds Management sold 1,336,368 Insmed shares in Q4 2022, an estimated $28.8M.
Fairmount Funds Management first reported a position in Insmed in Q4 2019 and held it in 12 quarters.
Fairmount Funds Management's Insmed position peaked at $45.8M in Q1 2022.
225 funds tracked by Wall St. Rank held Insmed as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.